IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00544804Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2
NCT00462956GW572016 In Patients With Advanced Or Metastatic Breast Cancer
NCT01133912Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb®) (PGT)
NCT00632489LBH589 in Combination With Capecitabine Plus/Minus (┬▒) Lapatinib in Breast Cancer Patients
NCT00807859Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
NCT00169533Rollover Study Of Lapatinib In Cancer Patients
NCT00085020GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu
NCT00513058Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer
NCT00379509Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer
NCT00790816Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
NCT00996762A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
NCT00359190Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer
NCT00753207Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30
NCT00984425The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors
NCT00371488GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer
NCT00495872Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
NCT00316875Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer
NCT00258050To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients